In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Heart failure patients may benefit from treatment of anaemia with Erythropoietin

ESC Congress 2009 - Heart Failure: hazards beyond the heart

• Ongoing trials (RED-HF and TREAT) study the efficacy of raising haemoglobin



Barcelona, Spain, 30 August: Heart failure patients may benefit from treatment of anaemia similarly to those with chronic kidney disease (CKD) or cancer.

Anaemia is common to many diseases (chronic kidney disease, cancer, chronic heart failure) as well as a consequence of treatment for diseases such as cancer, specifically with chemotherapeutic agents.  Anaemia may contribute to lethargy, reduced exercise tolerance and poor quality of life.  Therefore, raising haemoglobin (Hb) in anaemic patients has long been thought to be a beneficial therapeutic goal.
 
In contrast to CKD and cancer, attaining higher Hb targets does not appear to be associated with increased major events in early phase trials.  On the other hand, the incremental benefit on exercise tolerance was also not large in these studies.  Therefore, we are left with an equipoise situation in the treatment of the anaemia of heart failure, requiring a definitive outcome trial, which is currently occurring (RED-HF).

Erythropoietin is an endogenous hormone that raises Hb levels and various synthetic approaches have been developed to allow administration of this agent as a therapeutic.  Improvements in patient symptom status and quality-of-life have consistently been observed in the literature with erythropoietin across a number of disease categories.  However, a question has arisen as to whether there may be detrimental effects of raising Hb either too fast or to too high a level with these agents.  In particular, studies in patients with anaemia of cancer and the treatment of cancer as well as with those in CKD have demonstrated that higher Hb targets are associated with adverse clinical outcomes including death and major cardiovascular events. 

Prospective trials are needed to address this issue, by randomising patients to differing Hb targets and looking specifically at cardiovascular events.  Such an ongoing large-scale study is TREAT, which is looking at erythropoietin in CKD patients with diabetes. 

- Ends -

Notes to editor

This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2009. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology.